Deerfield Management Company, L.P. (Series C) Ligand Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 7,916 shares of LGND stock, worth $897,516. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,916Holding current value
$897,516% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LGND
# of Institutions
249Shares Held
17.7MCall Options Held
61KPut Options Held
7.8K-
Black Rock Inc. New York, NY2.87MShares$326 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$218 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$114 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3967KShares$110 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX709KShares$80.3 Million0.02% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.91B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...